Thromboprophylaxis for lung cancer patients - Multimodality assessment of clinician practices, perceptions and decision support tools

Supportive Care in Cancer

Volumn 22, Issue 7, 2014, Pages 1915-1922

  Alexander, M ^a,b   Kirsa, S ^a   MacManus, M ^a   Ball, D ^a,c   Solomon, B ^a,c   Burbury, K ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Chemotherapy; Lung cancer; Radiotherapy; Surgery; Thromboembolism; Thromboprophylaxis

Indexed keywords

ANTINEOPLASTIC AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; WARFARIN;

AMBULATORY CARE; ARTICLE; CANCER CHEMOTHERAPY; CHEMORADIOTHERAPY; CLINICAL PRACTICE; COMPRESSION INSTRUMENT; COMPRESSION STOCKING; COMPRESSION THERAPY; DECISION SUPPORT SYSTEM; HUMAN; LUNG CANCER; LUNG SURGERY; MEDICAL ONCOLOGIST; MULTIMODALITY CANCER THERAPY; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION ONCOLOGIST; RISK ASSESSMENT; SELF REPORT; SURGICAL ONCOLOGIST; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

AMBULATORY CARE; COMBINED MODALITY THERAPY; DATA COLLECTION; DECISION SUPPORT TECHNIQUES; HUMANS; LUNG NEOPLASMS; MULTIMODAL IMAGING; PHYSICIAN'S PRACTICE PATTERNS; SELF REPORT; THROMBOSIS;

EID: 84902373682     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2170-y     Document Type: Article

References (43)

1. GLOBOCAN 2008. Lung cancer incidence and mortality worldwide in 2008. International Agency for Research on Cancer. World Health Organisation. Accessed 10/10/13. Available: http://globocan.iarc.fr/factsheets/cancers/lung.asp
2. Rickles FR, Edwards RL (1983) Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62(1):14-31 (Pubitemid 13070586)
3. Corrales-Rodriguez L, Blais N (2012) Lung cancer associated venous thromboembolic disease: a comprehensive review. Lung cancer (Amsterdam, Netherlands) 75(1):1-8
4. Connolly GC, Dalal M, Lin J, Khorana AA (2012) Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung cancer 78(3):253-258
5. Huang H, Korn JR, Mallick R, Friedman M, Nichols C, Menzin J (2012) Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: a retrospective database study. J Thromb Thrombolysis 34(4):446-456
6. Lamy A, Wang X, Kent R, Smith KM, Gafni A (2002) Economic evaluation of the MEDENOX trial: a Canadian perspective. Medical patients with enoxaparin. Can Respir J 9(3):169-177 (Pubitemid 34863634)
7. Bergqvist D (2002) Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes. Pharmacoeconomics 20(4):225-243
8. Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH (2009) Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 27(29):4919-4926
9. Leavitt MO (2008) The surgeon general's call to action to prevent deep vein thrombosis and pulmonary embolism. U.S. Department of Health and Human Services (HHS) under the direction of the Office of the Surgeon General and the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. Accessed 10/10/13. Available: http://www.surgeongeneral.gov/library/ calls/deepvein/call-to-action-on-dvt-2008.pdf
10. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA Jr (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371(9610):387-394 (Pubitemid 351173321)
11. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH (2008) The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 6(4):601-608. doi:10.1111/j.1538-7836.2008.02908.x (Pubitemid 351404927)
12. Horsted F, West J, Grainge MJ (2012) Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 9(7):e1001275. doi:10.1371/journal.pmed.1001275
13. Hicks LK, Cheung MC, Ding K, Hasan B, Seymour L, LeMaitre A, Leighl NB, Shepherd FA (2009) Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer 115(23):5516-5525
14. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10(10):943-949
15. Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, Melzer N, Kakkar AK (2012) Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 18(2):159-165
16. Macbeth F, Noble S, Griffiths G, Chowdhury R, Rolfe C, Hood K, Linnane S, Moore B, Cohen D, Cowles R, Longo M, Knoyle D (2013) Preliminary results from the FRAGMATIC trial: a randomised phase III clinical trial investigating the effect of FRAGMin® added to standard therapy in patients with lung cancer [conference abstract MO27.02]. J Thorac Oncol 8, Supplement 2
17. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A (2013) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. doi:10.1200/jco.2013. 49.1118
18. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):381S-453S (Pubitemid 351894916)
19. Mandalà M, Falanga A, Roila F, Group ObotEGW (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol 22(6):vi85-vi92. doi:10.1093/annonc/mdr392
20. National Institute for Health and Care Excellence (NICE) Clinical Guideline 92 (2010) Venous thromboembolism: reducing the risk. National Collaborating Centre for Acute and Chronic Conditions, London
21. National Health and Medical Research Council (NHMRC) (2009) Clinical practice guideline for the prevention of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to Australian hospitals. National Health and Medical Research Council, Melbourne
22. Australia and New Zealand Working Party on the Management and Prevention of Venous Thromboembolism (2007) Prevention of venous thromboembolism: best practice guidelines for Australia and New Zealand, 4th edn. Health Education and Management Innovations, Sydney
23. Streiff MB (2010) The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res 125(2):S128-S133
24. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Buller HR (2013) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 11(1):56-70. doi:10.1111/jth.12070
25. Siragusa S, Armani U, Carpenedo M, Falanga A, Fulfaro F, Imberti D, Laurora R, Molinari AC, Prisco D, Silingardi M, Verso M, Visona A (2012) Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 129(5):e171-e176
26. Scarci M, Pilling J, Harrison-Phipps K, Tennyson C, Routledge T (2010) Right upper video-assisted thoracoscopic lobectomy for early stage lung cancer. Multimed Man Cardiothorac Surg. doi:10.1510/mmcts.2009.004333
27. Gagarine A, Urschel JD, Miller JD, Bennett WF, Young JE (2003) Preoperative and intraoperative factors predictive of length of hospital stay after pulmonary lobectomy. Ann Thorac Cardiovasc Surg 9(4):222-225
28. Wright CD, Gaissert HA, Grab JD, O 'Brien SM, Peterson ED, Allen MS (2008) Predictors of prolonged length of stay after lobectomy for lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk-adjustment model. Ann Thorac Surg 85(6):1857-1865. doi:10.1016/j.athoracsur.2008.03.024 (Pubitemid 351685610)
29. Ay C, Dunkler D, Simanek R, Thaler J, Koder S,Marosi C, Zielinski C, Pabinger I (2011) Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 29(15):2099-2103. doi:10.1200/jco.2010.32.8294
30. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902-4907
31. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I (2010) Prediction of venous thromboembolism in cancer patients. Blood 116(24):5377-5382. doi:10.1182/blood-2010-02-270116
32. Alexander M, Teoh KC, Lingaratnam S, Kirsa S, Mellor JD (2013) Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. Asia Pac J Clin Oncol 9(2):169-175. doi:10.1111/ajco.12013
33. Watts AC, Brenkel IJ (2005) A postal survey of current thromboprophylactic practices of consultant orthopaedic surgeons in the treatment of fracture of the hip. J Bone Joint Surg (Br) 87-B(3):296-300. doi:10.1302/0301-620x.87b3.15060 (Pubitemid 40424852)
34. Filtenborg Tvedskov T, Rasmussen MS, Wille-Jorgensen P (2001) Survey of the use of thromboprophylaxis in laparoscopic surgery in Denmark. Br J Surg 88(10):1413-1416 (Pubitemid 32955427)
35. Bryson DJ, Uzoigwe CE, Braybrooke J (2012) Thromboprophylaxis in spinal surgery: a survey. J Orthop Surg Res 7:14
36. Molnar RB, Jenkin DE, Millar MJ, Campbell D, Harris IA (2012) The Australian arthroplasty thromboprophylaxis survey. J Arthroplasty 27(2):173-179
37. Srinivasaiah N, Arsalani-Zadeh R, Monson JR (2012) Thromboprophylaxis in colorectal surgery: a National Questionnaire Survey of themembers of the Association of Coloproctology of Great Britain and Ireland. Colorectal Dis 14(7):e390-e393. doi:10.1111/j.1463-1318.2012.02974.x
38. Smart P, Burbury K, Lingaratnam S, Lynch AC, Mackay J, Heriot A (2012) Thromboprophylaxis among Australasian colorectal surgeons. ANZ J Surg 83(9):646-650
39. Wolff RA (2003) Are patients with cancer receiving adequate thromboprophylaxis? Results from FRONTLINE. Cancer Treat Rev 2:7-9
40. Hopkins L, Carrier M, Plante M, Luna V, Gotlieb W, Rambout L (2012) Surgical venous thromboprophylaxis: a cross-sectional survey of Canadian gynaecologic oncologists. J Obstet Gynaecol Can 34(7):673-677
41. Cavaliere L (2013) Thromboprophylaxis in ambulatory lung cancer treatment. Clin J Oncol Nurs 17(1):74-79. doi:10.1188/13.cjon.74-79
42. Sousou T, Khorana AA (2010) Cancer patients and awareness of venous thromboembolism. Cancer Invest 28(1):44-45. doi:10.3109/07357900902744544
43. Rose AJ, Sharman JP, Ozonoff A, Henault LE, Hylek EM (2007) Effectiveness of warfarin among patients with cancer. J Gen Intern Med 22(7):997-1002. doi:10.1007/s11606-007-0228-y (Pubitemid 46878624)